TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33507479

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Processing capacity
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Illness knowledge
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Knowledge
Number of subjects: 674
Study: 33507604

Group type: EXPERIMENTAL
Intervention: Vincristine and topotecan (VT) neoadjuvant intravenous chemotherapy
Number of subjects: 27
Study: 33507803

Group type: EXPERIMENTAL
Intervention: Autologous T-cell product targeting multiple tumor-associated antigens (TAAs) including PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1, administered at a fixed dose of 0.5 × 10^6 T cells, with a maximum tested dose of two infusions of 2 × 10^6 T cells
Number of subjects: 32
Study: 33507822

Group type: EXPERIMENTAL
Intervention: Mirdametinib (PD-0325901) at 2 mg/m, administered by mouth twice a day
Number of subjects: 19
Study: 33507832

Group type: EXPERIMENTAL
Intervention: Attention skills assessed by parent questionnaire (Child Behavior CheckList) and performance-based assessment (Conner's Continuous Performance Test-Second Edition)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standardized reading comprehension test (ORLEC Lobrot)
Number of subjects: 150

Group type: COMPARATOR
Intervention: NF1 group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-NF1 group
Number of subjects: 150
Study: 33508469

Group type: EXPERIMENTAL
Intervention: MDD-High CRP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: MDD (combined group)
Number of subjects: 132

Group type: COMPARATOR
Intervention: HC
Number of subjects: 132
Study: 33508475

Group type: EXPERIMENTAL
Intervention: Modified Duke criteria without transesophageal echocardiography
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Modified Duke criteria with transesophageal echocardiography
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography alone
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Modified Duke criteria, heart murmur, and intensive care therapy
Number of subjects: 261

Group type: COMPARATOR
Intervention: Patients with IE
Number of subjects: 261
Study: 33509098

Group type: EXPERIMENTAL
Intervention: i-ACT system
Number of subjects: 48
Study: 33509135

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), 10 sessions as part of normal clinical management.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls (no intervention).
Number of subjects: 64
Study: 33509155

Group type: EXPERIMENTAL
Intervention: FitSpirit PA intervention (motivational talks, turnkey running program, PA sessions, special events)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FitSpirit PA intervention
Number of subjects: 0
Study: 33509156

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 0
Study: 33509215

Group type: EXPERIMENTAL
Intervention: EMiC2 continuous veno-venous haemodialysis (CVVHD)
Number of subjects: 12
Study: 33509259

Group type: EXPERIMENTAL
Intervention: PTEN-ASD
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PTEN no-ASD
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: macro-ASD
Number of subjects: 61

Group type: COMPARATOR
Intervention: PTEN mutation groups
Number of subjects: 61
Study: 33509293

Group type: EXPERIMENTAL
Intervention: Data strengthening (DS) and modified WHO Safe Childbirth Checklist (mSCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation-based training and mentoring (PRONTO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) Collaborative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall integrated package of interventions
Number of subjects: 0
Study: 33509390

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 34
Study: 33509403

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staging classification
Number of subjects: 0
Study: 33509647

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with chemotherapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 + chemotherapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 + chemotherapy
Number of subjects: 5
Study: 33509737

Group type: EXPERIMENTAL
Intervention: Colonoscopy performed within 24 hours
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Overall patient management
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Independent predictors of mortality
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Definite or presumptive source of bleeding disclosed
Number of subjects: 1198
Study: 33509972

Group type: EXPERIMENTAL
Intervention: ABT-806
Number of subjects: 0
Study: 33510343

Group type: EXPERIMENTAL
Intervention: Specialized eHealth-based management service (CS)
Number of subjects: 2195

Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 2195
Study: 33510610

Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy for ET
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MRgFUS pallidotomy for PD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Autofocusing echo imaging technique
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MRgFUS lesioning
Number of subjects: 8
Study: 33510705

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33511161

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 33511299

Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)
Number of subjects: 0
Study: 33511479

Group type: EXPERIMENTAL
Intervention: KTR-group (kidney-transplanted recipients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: C-group (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: KTR-group
Number of subjects: 120

Group type: COMPARATOR
Intervention: C-group
Number of subjects: 120
Study: 33511576

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33511633

Group type: EXPERIMENTAL
Intervention: Telerehabilitation for primary pulmonary rehabilitation
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Telerehabilitation for primary rehabilitation compared to no rehabilitation
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Telerehabilitation for maintenance rehabilitation compared to no rehabilitation
Number of subjects: 1904
Study: 33512057

Group type: EXPERIMENTAL
Intervention: 7-day ECG patch monitor
Number of subjects: 35
Study: 33512323

Group type: EXPERIMENTAL
Intervention: Therapist-guided online therapy (1 session per week for 6 weeks, utilizing cognitive behavioral therapy and acceptance and commitment therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-help internet-based therapy (automatic weekly newsletter with self-help information and tips)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Therapist-guided online therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-help internet-based therapy
Number of subjects: 60
Study: 33512327

Group type: EXPERIMENTAL
Intervention: Individually tailored PA internet intervention arm
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nutrition and wellness internet control arm
Number of subjects: 43
Study: 33512414

Group type: EXPERIMENTAL
Intervention: CAR22 therapy (1 × 10^6 CAR+ T cells per kilogram targeting CD22)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CAR22 therapy
Number of subjects: 3
Study: 33512441

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrates or cryoprecipitates as prophylaxis (35% of patients, n=72)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ≥1 injection per week (18.1% of patients, n=37)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Home treatment (16.6% of patients, n=34)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Previous thrombotic event (37 patients, 18.1%)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Younger age and residence in Asia or Africa
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Thrombotic events reported
Number of subjects: 204
Study: 33512452

Group type: EXPERIMENTAL
Intervention: VLS-101 (antibody-drug conjugate targeting ROR1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: VLS-101
Number of subjects: 4
Study: 33512666

Group type: EXPERIMENTAL
Intervention: Risankizumab 90 or 180 mg every 12 weeks for at least 48 weeks
Number of subjects: 110
Study: 33512717

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 1125
Study: 33512741

Group type: EXPERIMENTAL
Intervention: Paxman scalp cooling (SC) device
Number of subjects: 15
Study: 33512794

Group type: EXPERIMENTAL
Intervention: MOWOOT device (intermittent colonic exo-peristalsis) used daily for 20 minutes over 4 weeks
Number of subjects: 92
Study: 33512804

Group type: EXPERIMENTAL
Intervention: Rome IV criteria
Number of subjects: 600

Group type: COMPARATOR
Intervention: Rome III criteria
Number of subjects: 600

Group type: COMPARATOR
Intervention: Potential Asia criteria
Number of subjects: 600
Study: 33512974

Group type: EXPERIMENTAL
Intervention: Marrow Stimulation (MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osteochondral Allograft (OCA) Transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid-based Scaffold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atelocollagen-based Gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronized Allogeneic Cartilage Scaffold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biosynthetic Hydrogel (PEG diacrylate and denatured fibrinogen)
Number of subjects: 0
Study: 33513026

Group type: EXPERIMENTAL
Intervention: Elacestrant 400 mg orally once daily
Number of subjects: 57
Study: 33513030

Group type: EXPERIMENTAL
Intervention: Daratumumab/lenalidomide/dexamethasone (D-Rd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daratumumab/bortezomib/dexamethasone (D-Vd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 0
Study: 33513187

Group type: EXPERIMENTAL
Intervention: Navina Smart (electronic transanal irrigation system)
Number of subjects: 89
Study: 33513294

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1096
Study: 33513367

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33513372

Group type: EXPERIMENTAL
Intervention: MATRix-RICE (rituximab 375 mg/m2) plus autologous HSCT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: MATRix-RICE plus autologous HSCT
Number of subjects: 79
Study: 33513373

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Number of subjects: 949

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 949

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 949
Study: 33513645

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 0
Study: 33513712

Group type: EXPERIMENTAL
Intervention: Xiaomi Domestic Wristbands for sleep tracking
Number of subjects: 0
Study: 33513935

Group type: EXPERIMENTAL
Intervention: TILT-123
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TILT-123 + anti-PD-1
Number of subjects: 0
Study: 33514428

Group type: EXPERIMENTAL
Intervention: Etanercept (EMBARK)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control (DESIR)
Number of subjects: 239
Study: 33514524

Group type: EXPERIMENTAL
Intervention: LY3321367 (TIM-3 mAb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY3321367 with LY300054 (anti-PD-L1 antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33515034

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Niacin, vitamin B-12, or folate intake
Number of subjects: 1249
Study: 33515055

Group type: EXPERIMENTAL
Intervention: Convective water vapor thermal energy therapy (WAVE)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 2
Study: 33515429

Group type: EXPERIMENTAL
Intervention: Inhibitors of Src Family Kinases (SFKs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of Inducible Nitric Oxide Synthase (iNOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of NADPH Oxidase 2 (NOX2)
Number of subjects: 0
Study: 33516161

Group type: EXPERIMENTAL
Intervention: GLE/PIB
Number of subjects: 109
Study: 33516189

Group type: EXPERIMENTAL
Intervention: Avoidance of over-eating
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Maintenance of a regular schedule
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Exercise almost every day
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Regular schedule almost every day
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Avoidance of over-eating half of the time
Number of subjects: 555
Study: 33516200

Group type: EXPERIMENTAL
Intervention: CADMaHL model development with input from stakeholders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CADMaHL model
Number of subjects: 0
Study: 33516211

Group type: EXPERIMENTAL
Intervention: QLQ-GINET21 questionnaire
Number of subjects: 199
Study: 33516215

Group type: EXPERIMENTAL
Intervention: Highest triglyceride quartile
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Highest TG:HDL quartile
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Lowest HDL cholesterol quartile
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Highest vs lowest triglyceride quartile (males)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Lowest vs highest HDL cholesterol quartile (females)
Number of subjects: 15773
Study: 33516247

Group type: EXPERIMENTAL
Intervention: Whole genome enrichment NGS from fecal samples
Number of subjects: 14
Study: 33516248

Group type: EXPERIMENTAL
Intervention: Cluster analysis of biological markers
Number of subjects: 116
Study: 33516560

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day for 8 weeks
Number of subjects: 143
Study: 33516721

Group type: EXPERIMENTAL
Intervention: Idelalisib interruption (≥ 2 interruptions)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Idelalisib interruption after ≥ 6 months of treatment
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Idelalisib interruption with dose reduction
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Time off therapy of ≥ 8%
Number of subjects: 408
Study: 33517043

Group type: EXPERIMENTAL
Intervention: Radiotherapy (conventional fractionation and hypofractionation); dose range: 43.4 to 71.0 Gy (median dose: 48.6 Gy); boost radiation therapy administered to 49 patients.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Increasing EQD2 per Gy (odds ratio [OR]: 1.58, 95% CI: 1.26-1.98; p < 0.001)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Current smoking status (OR: 25.48, 95% CI: 1.56-415.65; p = 0.023)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Prosthetic breast reconstruction (OR: 9.28, 95% CI: 1.84-46.70; p = 0.007)
Number of subjects: 314
Study: 33517185

Group type: EXPERIMENTAL
Intervention: Imatinib discontinuation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MR4.5
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low NK cell levels
Number of subjects: 31
Study: 33517477

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) discontinuation
Number of subjects: 260
Study: 33517701

Group type: EXPERIMENTAL
Intervention: Statin treatment on hospital admission (21.7%)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Continuation of prior statin treatment
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Initiation of statins during the first days after ICH
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Statins initiated at hospital discharge
Number of subjects: 1275
Study: 33517769

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years)
Number of subjects: 0
Study: 33518355

Group type: EXPERIMENTAL
Intervention: Ranolazine 375-750 mg (single-dose and multiple-dose)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 118
Study: 33518442

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Beliefs Scale (HLB)
Number of subjects: 0
Study: 33518523

Group type: EXPERIMENTAL
Intervention: Biomarkers (lactate, hs-cTnT, NT-proBNP, D-dimer, procalcitonin) measured on arrival.
Number of subjects: 450
Study: 33519187

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 40
Study: 33519339

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion (300 ml, 200-400 ml/treatment dose) at least once, up to 5 sessions, along with best standard of care.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Best standard of care only (control group).
Number of subjects: 40
Study: 33519425

Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention (3 units of 45 min) of aerobic exercise (AE)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 183
Study: 33519487

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33519659

Group type: EXPERIMENTAL
Intervention: Objective dual-task turning measures during assessments with inertial sensors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline assessment prior to rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-rehabilitation assessment after completion of rehabilitation
Number of subjects: 0
Study: 33519698

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33520317

Group type: EXPERIMENTAL
Intervention: Prolonged-release pirfenidone (PR-PFD) 1,200 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Prolonged-release pirfenidone (PR-PFD) 600 mg/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 33520402

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33520670

Group type: EXPERIMENTAL
Intervention: Blended transdiagnostic group CBT
Number of subjects: 30
Study: 33521019

Group type: EXPERIMENTAL
Intervention: Collagen Tripeptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33521037

Group type: EXPERIMENTAL
Intervention: Fermented High-Fiber Rye Diet
Number of subjects: 0
Study: 33521522

Group type: EXPERIMENTAL
Intervention: healthy plant-based diet index (hPDI)
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: unhealthy plant-based diet index (uPDI)
Number of subjects: 4680
Study: 33521534

Group type: EXPERIMENTAL
Intervention: Medical prescriptions for fresh vegetables (21 servings/week for 10 weeks)
Number of subjects: 159
Study: 33521537

Group type: EXPERIMENTAL
Intervention: Diet Risk Score (DRS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI)-2015
Number of subjects: 126
Study: 33521539

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Serum perfluorooctanesulfonic acid (PFOS) concentrations
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age group 30-39 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Serum PFASs
Number of subjects: 158
Study: 33521643

Group type: EXPERIMENTAL
Intervention: Liberal IV fluid regimen
Number of subjects: 161

Group type: COMPARATOR
Intervention: Restrictive IV fluid regimen
Number of subjects: 161
Study: 33521873

Group type: EXPERIMENTAL
Intervention: F-18 Flurpiridaz PET myocardial perfusion imaging (MPI)
Number of subjects: 0
Study: 33522296

Group type: EXPERIMENTAL
Intervention: Resilience training or support (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33522900

Group type: EXPERIMENTAL
Intervention: Saliva, plasma, and cerebrospinal fluid (CSF) samples from NeuP patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saliva, plasma, and cerebrospinal fluid (CSF) samples from healthy controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plasma proteins
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of YKL-40 and MIP-1α in saliva
Number of subjects: 13
Study: 33522962

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (in-person rehabilitation)
Number of subjects: 40
Study: 33522978

Group type: EXPERIMENTAL
Intervention: mHealth app for tracking hypertension
Number of subjects: 200

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trial My App platform
Number of subjects: 200
Study: 33523330

Group type: EXPERIMENTAL
Intervention: HOME Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 0
Study: 33523334

Group type: EXPERIMENTAL
Intervention: BI 836826 in combination with gemcitabine and oxaliplatin
Number of subjects: 0
Study: 33523367

Group type: EXPERIMENTAL
Intervention: Radiomic features from contrast-enhanced CT (ceCT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Radiomic features from non-contrast-enhanced CT (non-ceCT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Radiomic features from ceCT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Non-ceCT features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ceCT features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Conventional CT 'necrosis'
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Conventional CT 'arterial vascular invasion'
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional-imaged-based-parameters
Number of subjects: 39